{
     "PMID": "27291828",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20170619",
     "LR": "20180207",
     "IS": "1873-7064 (Electronic) 0028-3908 (Linking)",
     "VI": "109",
     "DP": "2016 Oct",
     "TI": "Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse.",
     "PG": "139-147",
     "LID": "S0028-3908(16)30250-7 [pii] 10.1016/j.neuropharm.2016.06.010 [doi]",
     "AB": "Histaminergic H3 receptors (H3R) antagonists enhance cognition in preclinical models and modulate neurotransmission, in particular acetylcholine (ACh) release in the cortex and hippocampus, two brain areas involved in memory processing. The cognitive deficits seen in aging and Alzheimer's disease have been associated with brain cholinergic deficits. Donepezil is one of the acetylcholinesterase (AChE) inhibitor approved for use across the full spectrum of these cognitive disorders. We addressed the question if H3R antagonists and donepezil require an intact histamine neuronal system to exert their procognitive effects. The effect of the H3R antagonist ABT-239 and donepezil were evaluated in the object recognition test (ORT), and on the level of glycogen synthase kinase 3 beta (GSK-3beta) phosphorylation in normal and histamine-depleted mice. Systemic administration of ABT-239 or donepezil ameliorated the cognitive performance in the ORT. However, these compounds were ineffective in either genetically (histidine decarboxylase knock-out, HDC-KO) or pharmacologically, by means of intracerebroventricular (i.c.v.) injections of the HDC irreversible inhibitor a-fluoromethylhistidine (a-FMHis), histamine-deficient mice. Western blot analysis revealed that ABT-239 or donepezil systemic treatments increased GSK-3beta phosphorylation in cortical and hippocampal homogenates of normal, but not of histamine-depleted mice. Furthermore, administration of the PI3K inhibitor LY294002 that blocks GSK-3beta phosphorylation, prevented the procognitive effects of both drugs in normal mice. Our results indicate that both donepezil and ABT-239 require the integrity of the brain histaminergic system to exert their procognitive effects and strongly suggest that impairments of PI3K/AKT/GSK-3beta intracellular pathway activation is responsible for the inefficacy of both drugs in histamine-deficient animals.",
     "CI": [
          "Copyright (c) 2016 Elsevier Ltd. All rights reserved."
     ],
     "FAU": [
          "Provensi, Gustavo",
          "Costa, Alessia",
          "Passani, M Beatrice",
          "Blandina, Patrizio"
     ],
     "AU": [
          "Provensi G",
          "Costa A",
          "Passani MB",
          "Blandina P"
     ],
     "AD": "Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmacologia and Tossicologia, Universita di Firenze, Viale G. Pieraccini 6, 50139, Firenze, Italy. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmacologia and Tossicologia, Universita di Firenze, Viale G. Pieraccini 6, 50139, Firenze, Italy. Dipartimento di Scienze della Salute, Sezione di Farmacologia e Oncologia, Universita di Firenze, Viale G. Pieraccini 6, 50139, Firenze, Italy. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmacologia and Tossicologia, Universita di Firenze, Viale G. Pieraccini 6, 50139, Firenze, Italy. Electronic address: patrizio.blandina@unifi.it.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20160610",
     "PL": "England",
     "TA": "Neuropharmacology",
     "JT": "Neuropharmacology",
     "JID": "0236217",
     "RN": [
          "0 (Benzofurans)",
          "0 (Cholinesterase Inhibitors)",
          "0 (Histamine H3 Antagonists)",
          "0 (Indans)",
          "0 (Nootropic Agents)",
          "0 (Piperidines)",
          "0 (Pyrrolidines)",
          "0 (Receptors, Histamine H3)",
          "820484N8I3 (Histamine)",
          "86H6B395PI (benzonitrile,",
          "4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-)",
          "8SSC91326P (donepezil)",
          "EC 4.1.1.22 (Histidine Decarboxylase)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Benzofurans/*pharmacology",
          "Brain/drug effects/*metabolism",
          "Cholinesterase Inhibitors/*pharmacology",
          "Cognition/drug effects/physiology",
          "Drug Inverse Agonism",
          "Histamine/*deficiency",
          "Histamine H3 Antagonists/*pharmacology",
          "Histidine Decarboxylase/antagonists & inhibitors/deficiency",
          "Indans/*pharmacology",
          "Male",
          "Mice",
          "Mice, Knockout",
          "Nootropic Agents/*pharmacology",
          "Piperidines/*pharmacology",
          "Pyrrolidines/*pharmacology",
          "Receptors, Histamine H3/metabolism"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "*Acetylcholine",
          "*GSK-3beta",
          "*HDC-KO mice",
          "*Memory",
          "*Object recognition test",
          "*a-fluoromethylhistidine"
     ],
     "EDAT": "2016/06/14 06:00",
     "MHDA": "2017/06/20 06:00",
     "CRDT": [
          "2016/06/14 06:00"
     ],
     "PHST": [
          "2016/02/18 00:00 [received]",
          "2016/06/06 00:00 [revised]",
          "2016/06/08 00:00 [accepted]",
          "2016/06/14 06:00 [entrez]",
          "2016/06/14 06:00 [pubmed]",
          "2017/06/20 06:00 [medline]"
     ],
     "AID": [
          "S0028-3908(16)30250-7 [pii]",
          "10.1016/j.neuropharm.2016.06.010 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuropharmacology. 2016 Oct;109:139-147. doi: 10.1016/j.neuropharm.2016.06.010. Epub 2016 Jun 10.",
     "term": "hippocampus"
}